124 related articles for article (PubMed ID: 30980260)
21. Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial.
Monk BJ; Colombo N; Oza AM; Fujiwara K; Birrer MJ; Randall L; Poddubskaya EV; Scambia G; Shparyk YV; Lim MC; Bhoola SM; Sohn J; Yonemori K; Stewart RA; Zhang X; Perkins Smith J; Linn C; Ledermann JA
Lancet Oncol; 2021 Sep; 22(9):1275-1289. PubMed ID: 34363762
[TBL] [Abstract][Full Text] [Related]
22. Effect of chemotherapy on circulating gastrointestinal hormone levels in ovarian cancer patients: relationship to nausea and vomiting.
Hursti TJ; Börjeson S; Hellström PM; Avall-Lundqvist E; Stock S; Steineck G; Peterson C
Scand J Gastroenterol; 2005 Jun; 40(6):654-61. PubMed ID: 16036525
[TBL] [Abstract][Full Text] [Related]
23. Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer.
Moore KN; Birrer MJ; Marsters J; Wang Y; Choi Y; Royer-Joo S; Lemahieu V; Armstrong K; Cordova J; Samineni D; Schuth E; Vaze A; Maslyar D; Humke EW; Hamilton EP; Liu JF
Gynecol Oncol; 2020 Sep; 158(3):631-639. PubMed ID: 32534811
[TBL] [Abstract][Full Text] [Related]
24. A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer.
Monk BJ; Herzog TJ; Wang G; Triantos S; Maul S; Knoblauch R; McGowan T; Shalaby WSW; Coleman RL
Gynecol Oncol; 2020 Mar; 156(3):535-544. PubMed ID: 31924332
[TBL] [Abstract][Full Text] [Related]
25. Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide.
Shih V; Wan HS; Chan A
Ann Pharmacother; 2009 Mar; 43(3):444-52. PubMed ID: 19193584
[TBL] [Abstract][Full Text] [Related]
26. A phase II study of lenalidomide in platinum-sensitive recurrent ovarian carcinoma.
Selle F; Sevin E; Ray-Coquard I; Mari V; Berton-Rigaud D; Favier L; Fabbro M; Lesoin A; Lortholary A; Pujade-Lauraine E
Ann Oncol; 2014 Nov; 25(11):2191-2196. PubMed ID: 25210017
[TBL] [Abstract][Full Text] [Related]
27. Phase II trial of bryostatin-1 in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: a California cancer consortium study.
Morgan RJ; Leong L; Chow W; Gandara D; Frankel P; Garcia A; Lenz HJ; Doroshow JH
Invest New Drugs; 2012 Apr; 30(2):723-8. PubMed ID: 20936324
[TBL] [Abstract][Full Text] [Related]
28. Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelian ovarian cancer patients. Long-term single institution experience and literature review.
García-Sáenz JA; Custodio A; Casado A; Vidart JA; Coronado PJ; Martín M; López-Tarruella S; Puente J; Fernández C; Díaz-Rubio E
Clin Transl Oncol; 2011 Feb; 13(2):121-32. PubMed ID: 21324801
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of the validity of chemotherapy-induced nausea and vomiting assessment in outpatients using the Japanese version of the MASCC antiemesis tool.
Matsuda Y; Okita K; Furuhata T; Kutomi G; Yamashita K; Sato Y; Takimoto R; Hirata K
Support Care Cancer; 2015 Nov; 23(11):3331-9. PubMed ID: 26003425
[TBL] [Abstract][Full Text] [Related]
30. Impact of initiating antiemetic prophylaxis with palonosetron versus ondansetron on risk of uncontrolled chemotherapy-induced nausea and vomiting in patients with lung cancer receiving multi-day chemotherapy.
Feinberg B; Gilmore J; Haislip S; Jackson J; Jain G; Balu S; Buchner D
Support Care Cancer; 2012 Mar; 20(3):615-23. PubMed ID: 21761096
[TBL] [Abstract][Full Text] [Related]
31. Incidence of chemotherapy-induced nausea and vomiting among cancer patients receiving moderately to highly emetogenic chemotherapy in cancer centers in Sichuan, China.
Sun Y; Zheng Y; Yang X; Xie K; Du C; He L; Gui Y; Fu J; Li C; Zhang H; Zhu L; Bie J; Sun Y; Fu Y; Zhou Y; Shou F; Wang Y; Zhu J
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2701-2708. PubMed ID: 33586045
[TBL] [Abstract][Full Text] [Related]
32. Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma.
Oza AM; Lorusso D; Aghajanian C; Oaknin A; Dean A; Colombo N; Weberpals JI; Clamp AR; Scambia G; Leary A; Holloway RW; Gancedo MA; Fong PC; Goh JC; O'Malley DM; Armstrong DK; Banerjee S; García-Donas J; Swisher EM; Cella D; Meunier J; Goble S; Cameron T; Maloney L; Mörk AC; Bedel J; Ledermann JA; Coleman RL
J Clin Oncol; 2020 Oct; 38(30):3494-3505. PubMed ID: 32840418
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of non-completion of intraperitoneal chemotherapy in patients with advanced epithelial ovarian cancer.
Chambers LM; Son J; Radeva M; DeBernardo R
J Gynecol Oncol; 2019 Nov; 30(6):e93. PubMed ID: 31576687
[TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of aprepitant, ramosetron, and dexamethasone for chemotherapy-induced nausea and vomiting in patients with ovarian cancer treated with paclitaxel/carboplatin.
Choi CH; Kim MK; Park JY; Yoon A; Kim HJ; Lee YY; Kim TJ; Lee JW; Kim BG; Bae DS
Support Care Cancer; 2014 May; 22(5):1181-7. PubMed ID: 24337621
[TBL] [Abstract][Full Text] [Related]
35. The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting.
Dranitsaris G; Molassiotis A; Clemons M; Roeland E; Schwartzberg L; Dielenseger P; Jordan K; Young A; Aapro M
Ann Oncol; 2017 Jun; 28(6):1260-1267. PubMed ID: 28398530
[TBL] [Abstract][Full Text] [Related]
36. Genetic risk factors for chemotherapy-induced nausea and vomiting in patients with cancer receiving cisplatin-based chemotherapy.
Yokoi M; Tsuji D; Suzuki K; Kawasaki Y; Nakao M; Ayuhara H; Kogure Y; Shibata K; Hayashi T; Hirai K; Inoue K; Hama T; Takeda K; Nishio M; Itoh K
Support Care Cancer; 2018 May; 26(5):1505-1513. PubMed ID: 29177570
[TBL] [Abstract][Full Text] [Related]
37. Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer.
van der Burg ME; Onstenk W; Boere IA; Look M; Ottevanger PB; de Gooyer D; Kerkhofs LG; Valster FA; Ruit JB; van Reisen AG; Goey SH; van der Torren AM; ten Bokkel Huinink D; Kok TC; Verweij J; van Doorn HC
Eur J Cancer; 2014 Oct; 50(15):2592-601. PubMed ID: 25096168
[TBL] [Abstract][Full Text] [Related]
38. Have Volume-based Parameters of Positron Emission Tomography/Computed Tomography Prognostic Relevance for Patients With Potentially Platinum-responsive Recurrent Ovarian Cancer? A Single Center Italian Study.
Gadducci A; Simonetti E; Guidoccio F; Manca G; Giorgetti A; Depalo T; Cosio S; Miccoli M; Volterrani D
Anticancer Res; 2021 Apr; 41(4):1937-1944. PubMed ID: 33813399
[TBL] [Abstract][Full Text] [Related]
39. Clinical outcomes in ovarian cancer patients receiving three versus more cycles of chemotherapy after neoadjuvant treatment and interval cytoreductive surgery.
Kim JS; Liang MI; Prendergast EN; Alldredge J; Datta A; Hurteau JA; Kirschner CV; Rodriguez G; Vogel TJ; Brooks RA; Cass I; Cohen JG; Penner KR; Wang CE; Diaz Moore ES
Int J Gynecol Cancer; 2019 Sep; 29(7):1156-1163. PubMed ID: 31352365
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of aprepitant in patients with advanced or recurrent lung cancer receiving moderately emetogenic chemotherapy.
Uchino J; Hirano R; Tashiro N; Yoshida Y; Ushijima S; Matsumoto T; Ohta K; Nakatomi K; Takayama K; Fujita M; Nakanishi Y; Watanabe K
Asian Pac J Cancer Prev; 2012; 13(8):4187-90. PubMed ID: 23098425
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]